

Pretreatment with vaginal misoprostol before vacuum aspiration

Submission date 22/03/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 01/04/2004	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 10/10/2014	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Helena von Hertzen

Contact details
World Health Organization
20 Avenue Appia
Geneva-27
Switzerland
CH-1211
vonhertzenh@who.int

Additional identifiers

Protocol serial number
WHO/HRP ID A15066

Study information

Scientific Title

Study objectives

To evaluate if vaginal administration of 0.4 mg misoprostol facilitates cervical dilation, reduces complications of first trimester induced abortion, and is acceptable to women.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Induced abortion

Interventions

Misoprostol (0.4 mg) versus placebo tablet three hours before vacuum aspiration. Approximate duration of involvement in the study for each subject is one follow up visit ten days post-treatment.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Misoprostol

Primary outcome(s)

Will evaluate if preoperative treatment with 0.4 mg misoprostol administered vaginally three hours before vacuum aspiration can reduce complications of surgical first trimester abortion.

Key secondary outcome(s)

No secondary outcome measures

Completion date

01/12/2002

Eligibility**Key inclusion criteria**

1. Pregnancy of less than 12 completed weeks
2. Be informed about the study and sign a consent form
3. Agree to return for a follow-up visit five to ten days after surgery

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

No exclusion criteria

Date of first enrolment

01/12/2001

Date of final enrolment

01/12/2002

Locations**Countries of recruitment**

Armenia

China

Cuba

Hungary

India

Mongolia

Romania

Slovenia

Switzerland

Viet Nam

Study participating centre
World Health Organization
Geneva-27
Switzerland
CH-1211

Sponsor information

Organisation

UNDP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction

ROR

<https://ror.org/01f80g185>

Funder(s)

Funder type

Research organisation

Funder Name

United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA) /World Health Organization (WHO)/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction (HRP)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	12/05/2012		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes